PCSK9 and atherosclerosis: In 2015, the FDA approved two PCSK9 inhibitors, Alirocumab and Evolocumab, for adults with familial hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease (ASCVD) who need further LDL-C reduction [5,6].